HIV Vaccines

IL-7 May Be Important in Future Immune-Based Therapies

Published in Vaccine Weekly, October 9th, 1995

Interleukin-7 (IL-7) may be important in future immune-based therapies involving large scale antigen-specific effector cell activation/expansion, according to a report from Durham, North Carolina's Duke University.

CD8⁺ cytotoxic T lymphocytes (CTL) are an important component in the immunologic control of human viral disease. IL-7, a stromal cell-derived cytokine, has been demonstrated to enhance both anti-tumor and anti-viral CTL as well as lymphokine-activated killer (LAK) activity.

In this study researcher G. Ferrari examined the ability of IL-7 to support the activation and the growth of in vitro antigen-specific CTL precursors (CTLp)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-10-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry